See more : Emperor Metals Inc. (AUOZ.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Alpine Immune Sciences, Inc. (ALPN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpine Immune Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RenetJapanGroup,Inc. (3556.T) Income Statement Analysis – Financial Results
- United Lithium Corp. (ULTH.CN) Income Statement Analysis – Financial Results
- Atlas Crest Investment Corp. II (ACIIW) Income Statement Analysis – Financial Results
- Promotora Ambiental, S.A.B. de C.V. (PASAB.MX) Income Statement Analysis – Financial Results
- Westell Technologies, Inc. (WSTL) Income Statement Analysis – Financial Results
Alpine Immune Sciences, Inc. (ALPN)
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.88M | 30.06M | 23.44M | 9.34M | 1.74M | 705.00K | 1.73M | 2.95M | 492.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 80.90M | 597.00K | 620.00K | 27.19M | 35.85M | 28.97M | 10.63M | 143.00K | 66.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.03M | 29.47M | 22.82M | -17.85M | -34.11M | -28.27M | -8.90M | 2.81M | 426.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -37.41% | 98.01% | 97.36% | -191.22% | -1,960.17% | -4,009.22% | -513.86% | 95.15% | 86.59% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.90M | 70.24M | 58.74M | 27.19M | 35.85M | 28.97M | 10.63M | 23.32M | 16.05M | 12.20M | 13.14M | 7.10M |
| General & Administrative | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Other Expenses | 0.00 | -97.00K | -4.00K | 1.33M | 812.00K | 1.20M | 0.00 | 0.00 | 80.00K | 296.34K | 0.00 | 150.94K |
| Operating Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Cost & Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Interest Income | 11.85M | 3.29M | 259.00K | 245.00K | 1.25M | 1.30M | 542.00K | 439.00K | 80.00K | 0.00 | 10.00K | 0.00 |
| Interest Expense | 98.00K | 476.00K | 816.00K | 775.00K | 338.00K | 319.00K | 152.00K | 0.00 | 0.00 | 845.10K | 931.00K | 694.07K |
| Depreciation & Amortization | 576.00K | 3.19M | 255.00K | 1.58M | 2.06M | 388.00K | 241.00K | 143.00K | 66.00K | 86.44K | 219.00K | 212.03K |
| EBITDA | -43.67M | -54.96M | -49.60M | -27.17M | -41.51M | -35.33M | -14.19M | -31.90M | -22.90M | -14.10M | -15.05M | -8.67M |
| EBITDA Ratio | -74.18% | -182.80% | -211.59% | -291.07% | -2,385.86% | -5,011.49% | -819.82% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Operating Income | -44.25M | -58.15M | -49.86M | -28.75M | -43.57M | -37.83M | -14.97M | -31.90M | -22.90M | -14.49M | -15.28M | -9.03M |
| Operating Income Ratio | -75.16% | -193.41% | -212.68% | -307.97% | -2,504.25% | -5,365.96% | -865.05% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.17M | 2.72M | -561.00K | 803.00K | 1.72M | 977.00K | 6.99M | 439.00K | 80.00K | -548.76K | -921.00K | -543.14K |
| Income Before Tax | -32.08M | -55.43M | -50.42M | -27.95M | -41.85M | -36.85M | -7.98M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Income Before Tax Ratio | -54.49% | -184.38% | -215.07% | -299.37% | -2,405.29% | -5,227.38% | -461.18% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 103.00K | 2.33M | -87.00K | -6.00K | 682.00K | -366.00K | -200.00K | -143.00K | -66.00K | 1.14M | 941.00K | 845.01K |
| Net Income | -32.18M | -57.76M | -50.33M | -27.94M | -42.53M | -36.49M | -7.78M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Net Income Ratio | -54.66% | -192.13% | -214.70% | -299.30% | -2,444.48% | -5,175.46% | -449.62% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| EPS Diluted | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| Weighted Avg Shares Out | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
Wall Street Analysts Believe Alpine Immune Sciences, Inc. (ALPN) Could Rally 50.37%: Here's is How to Trade
The mean of analysts' price targets for Alpine Immune Sciences, Inc. (ALPN) points to a 50.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate...
Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023. He...
Here's Why You Should Invest in Alpine (ALPN) Stock Now
Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company presented new preclinical data from a study of povetacicept in a murine experimental autoimmune...
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences. Thursday, September 7th, the Company will...
Alpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company will present new preclinical data from a study of povetacicept in a murine experimental...
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the successful initiation of the second IgA nephropathy (IgAN) dose cohort in RUBY-3, a phase 1b/2a study...
Alpine Immune Sciences, Inc. (ALPN) Is a Great Choice for 'Trend' Investors, Here's Why
Alpine Immune Sciences, Inc. (ALPN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of M. Christina Yi to Chief Technology Officer effective August 21, 2023. Ms. Yi...
Source: https://incomestatements.info
Category: Stock Reports